BC
TLIS

Boxer Capital’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Boxer Capital’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-103,400
Closed -$9.69M – 90
2021
Q3 		$9.69M Hold
103,400
– – 0.34% 61
2021
Q2 		$17.1M Hold
103,400
– – 0.6% 53
2021
Q1 		$19.9M Buy
+103,400
New +$25.8M 0.68% 43

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Boxer Capital's TLIS Position: Q4 2021 in Review

Boxer Capital sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q4 2021, closing a stake of 103,400 shares — an estimated $9.69M sold.

Boxer Capital first reported a position in TLIS in Q1 2021 and held it in 3 quarters. The position peaked at $19.9M in Q1 2021. 46 funds tracked by Wall St. Rank hold TLIS as of Q4 2021.

  • Boxer Capital reported no remaining Talis Biomedical Corporation Common Stock position as of Q4 2021 after selling out during the quarter.
  • Boxer Capital sold 103,400 Talis Biomedical Corporation Common Stock shares in Q4 2021, an estimated $9.69M.
  • Boxer Capital first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 3 quarters.
  • Boxer Capital's Talis Biomedical Corporation Common Stock position peaked at $19.9M in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q4 2021.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.